Adult Immunization Allergy & Immunology Cardiology Dermatology Endocrinology Gastroenterology Infectious Disease Men’s Health Nephrology Neurology Pain Management Pediatric Immunization Pediatrics Psychiatry Pulmonology Rheumatology Women’s Health

Billing and Collections Career Planning Coding and Documentation Concierge Medicine Cybersecurity EHRs Investing Patient Relations Personal Finance Practice Management Remote Patient Monitoring Staffing Technology Telehealth Value-based Care

Unmet Needs in Managing MDD Interpreting Thyroid Function Tests Using Thyroid Lab Tests Testing & Screening to Optimize Men's Health

Empowering Early Intervention: Navigating Treatments for Delaying T1D Progression, Insights from UC San Diego Health : Episode 8

Teplizumab Infusion Protocol: Clinical Processes and Strategies for Infusion Access Enhancement

June 11, 2024

By Jennifer D. Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP
Steven Edelman, MD

Opinion

Video

Focusing on the utilization of teplizumab, the expert panel from UCSD shares insights in how to select patients for this treatment and provide practical tips for the infusion process, and infusion location options.

EP: 1.Insights into the Burden of T1D: Genetic Links and Familial Considerations from UCSD Practitioners

EP: 2.The Vital Importance of Understanding and Addressing Training Gaps in Endocrinology Surrounding T1D Stages

EP: 3.The Crucial Impact of Early Intervention in Preventing T1D Stage Progression

EP: 4.Navigating T1D Risk Screening: Identifying Ideal Candidates, Understanding Autoantibodies, and Determining Timing for Rescreening

EP: 5.Understanding Autoantibody Screening Tests: Methods, Interpretation, and Analysis Practicalities

EP: 6.Exploring the First FDA-Approved Treatment to Delay T1D Onset: Mechanism of Action and Treatment Impact

EP: 7.Exploring the TN-10 Teplizumab Clinical Trial: Patient Demographics and Efficacy Insights

EP: 8.Teplizumab Infusion Protocol: Clinical Processes and Strategies for Infusion Access Enhancement

EP: 9.Key Insights and Practical Tips: Wisdom from UCSD Practitioners for Effective T1D Management

Recent Videos

New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time

Related Content

Mediterranean Diet Associated with Improved Cardiometabolic Health in Youth / Image credit: ©aamulya/AdobeStock

Mediterranean Diet Associated with Improved Cardiometabolic Health in Youth, According to First Meta-Analysis of its Kind

Sydney Jennings

Adherence to Mediterranean diet-based interventions was associated with reductions in BP, triglycerides, total cholesterol, and LDL-C, as well as increases in HDL-C among children and adolescents.

Man With Newly Diagnosed Type 2 Diabetes: What HbA1c Goal-And How to Get There?

Edward J. Shahady, MD

The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?

Immunotherapy to Delay, Treat Type 1 Diabetes Wins FDA Fast Track Designation

Immunotherapy to Delay, Treat Type 1 Diabetes Wins FDA Fast Track Designation

The antigen-specific immunotherapy preserves endogenous insulin production via intralymphatic injection of recombinant GAD65 protein, according to Diamyd Medical.

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Edward J. Shahady, MD

Hypoglycemia in type 2 diabetes patients can be the result of insulin or sulfonylureas.

Remaining Free of Diabetes for at Least 4 Years Improves Long-Term Health in Persons with Impaired Glucose Tolerance

Remaining Free of Diabetes for at Least 4 Years Improves Long-Term Health in Persons with Impaired Glucose Tolerance

Sydney Jennings

Long-term risk of death decreased by 26% and risk for vascular complications decreased by 40% in persons who remained diabetes-free for 4 years, according to new data.

FDA Issues CRL to Novo Nordisk for Once-Weekly Insulin Icodec

FDA Issues CRL to Novo Nordisk for Once-Weekly Insulin Icodec

The agency is concerned about manufacturing processes involved in production and about the proposed indication for adults with type 1 diabetes.

Related Content

Mediterranean Diet Associated with Improved Cardiometabolic Health in Youth / Image credit: ©aamulya/AdobeStock

Mediterranean Diet Associated with Improved Cardiometabolic Health in Youth, According to First Meta-Analysis of its Kind

Sydney Jennings

Adherence to Mediterranean diet-based interventions was associated with reductions in BP, triglycerides, total cholesterol, and LDL-C, as well as increases in HDL-C among children and adolescents.

Man With Newly Diagnosed Type 2 Diabetes: What HbA1c Goal-And How to Get There?

Edward J. Shahady, MD

The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?

Immunotherapy to Delay, Treat Type 1 Diabetes Wins FDA Fast Track Designation

Immunotherapy to Delay, Treat Type 1 Diabetes Wins FDA Fast Track Designation

The antigen-specific immunotherapy preserves endogenous insulin production via intralymphatic injection of recombinant GAD65 protein, according to Diamyd Medical.

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Edward J. Shahady, MD

Hypoglycemia in type 2 diabetes patients can be the result of insulin or sulfonylureas.

Remaining Free of Diabetes for at Least 4 Years Improves Long-Term Health in Persons with Impaired Glucose Tolerance

Remaining Free of Diabetes for at Least 4 Years Improves Long-Term Health in Persons with Impaired Glucose Tolerance

Sydney Jennings

Long-term risk of death decreased by 26% and risk for vascular complications decreased by 40% in persons who remained diabetes-free for 4 years, according to new data.

FDA Issues CRL to Novo Nordisk for Once-Weekly Insulin Icodec

FDA Issues CRL to Novo Nordisk for Once-Weekly Insulin Icodec

The agency is concerned about manufacturing processes involved in production and about the proposed indication for adults with type 1 diabetes.

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.